文献速递淋巴瘤

替代性RelB NF-κB亚基在弥漫性大B细胞淋巴瘤中的关键作用

The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma.
PubMed 文献 · Blood · 2022-01-01

该研究在大量DLBCL患者及细胞系中发现RelB频繁激活,且不依赖ABC或GCB亚型;RelB活化定义了具有独特基因表达谱和突变模式的新患者亚群,与MCD遗传亚型不相关,该亚群免疫化疗后预后极差。功能研究显示RelB通过cIAP2高表达赋予DLBCL细胞对多柔比星诱导DNA损伤凋亡的抵抗。

要点

  • RelB激活在DLBCL中频繁发生,独立于ABC/GCB亚型。
  • RelB阳性定义新亚群,免疫化疗后预后差。
  • RelB通过cIAP2高表达抵抗多柔比星凋亡。

核心结论

  • RelB激活可细化DLBCL预后分层,并可能参与颠覆部分患者的DNA损伤治疗反应。

研究设计与样本

  • 研究在大量DLBCL患者队列和细胞系中分析替代性NF-κB激活状态及其作用。

主要发现

  • 在大量DLBCL患者和细胞系中观察到RelB频繁激活,独立于ABC或GCB亚型。
  • RelB活性定义了一个具有独特基因表达谱和突变模式的新DLBCL患者亚群。
  • RelB激活与MCD遗传亚型不相关,该亚型富集携带MYD88L265P和CD79B突变、协同激活经典NF-κB的ABC肿瘤。
  • 新定义的RelB阳性DLBCL患者亚群免疫化疗后预后极差。
  • RelB赋予DLBCL细胞对多柔比星诱导DNA损伤凋亡的抵抗,且RelB阳性与cIAP2高表达相关。

临床怎么用

  • RelB激活状态可用于细化DLBCL患者的预后分层。
  • RelB阳性可能提示对含多柔比星方案DNA损伤应答受损。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoid malignancy affecting adults. The NF-κB transcription factor family is activated by 2 main pathways, the canonical and the alternative NF-κB activation pathway, with different functions. The alternative NF-κB pathway leads to activation of the transcriptionally active RelB NF-κB subunit. Alternative NF-κB activation status and its role in DLBCL pathogenesis remain undefined. Here, we reveal a frequent activation of RelB in a large cohort of DLBCL patients and cell lines, independently of their activated B-cell-like or germinal center B-cell-like subtype. RelB activity defines a new subset of patients with DLBCL and a peculiar gene expression profile and mutational pattern. Importantly, RelB activation does not correlate with the MCD genetic subtype, enriched for activated B-cell-like tumors carrying MYD88L265P and CD79B mutations that cooperatively activate canonical NF-κB, thus indicating that current genetic tools to evaluate NF-κB activity in DLBCL do not provide information on the alternative NF-κB activation. Furthermore, the newly defined RelB-positive subgroup of patients with DLBCL exhibits a dismal outcome after immunochemotherapy. Functional studies revealed that RelB confers DLBCL cell resistance to DNA damage-induced apoptosis in response to doxorubicin, a genotoxic agent used in the front-line treatment of DLBCL. We also show that RelB positivity is associated with high expression of cellular inhibitor of apoptosis protein 2 (cIAP2). Altogether, RelB activation can be used to refine the prognostic stratification of DLBCL and may contribute to subvert the therapeutic DNA damage response in a segment of patients with DLBCL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Eluard B, Nuan-Aliman S, Faumont N, et al. The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma. Blood. 2022. PMID: 34232979. doi:10.1182/blood.2020010039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。